Overview

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

Status:
Completed
Trial end date:
2016-07-16
Target enrollment:
Participant gender:
Summary
A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Collaborators:
Hospira, Inc.
Hospira, now a wholly owned subsidiary of Pfizer
Treatments:
Epoetin Alfa